---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-147030"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:39:19.942206+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology completes enrollment of 85 patients in Phase 2 KOMET-001 trial; topline data expected early 2025

## Summary
- Final enrollment of 85 patients in Phase 2 registration-directed trial of menin inhibitor ziftomenib for NPM1-mutant AML.
- Topline data from KOMET-001 trial expected in early 2025.
- Trial targets relapsed/refractory NPM1-mutant acute myeloid leukemia.

## SEC filing metadata
- accession: 0001193125-24-147030
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/0001193125-24-147030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312524147030/d842527d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-147030
- JSON: https://secwatch.observer/filing/0001193125-24-147030.json
- Plain text: https://secwatch.observer/filing/0001193125-24-147030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.